Back to results
US 11,453,696 B2Granted
Adenosine analogs as methyltransferase inhibitors for treating cancer
AssigneeMemorial Sloan Kettering Cancer Center
InventorsMinkui Luo, Xiaochuan Cai, Ke Wang, Junyi Wang
Life of this patent
Estimating the term…
Abstract
Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structures The compounds disclosed are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
Claims20
A pharmaceutical composition, comprising
- a) a compound of formula I or II
- wherein:
- A is chosen from a direct bond and a (C1-C10)hydrocarbon;
- Y is N or CH;
- R2 is chosen from —H, and optionally substituted aryl and heteroaryl;
- R3 is chosen from
- —((CH2)m)aryl substituted with one to three substituents chosen independently from (C1-C6)alkoxy, halo(C1-C6)alkoxy, methylenedioxy, ethylendioxy, (C1-C6)acyl, (C1-C6)alkoxyalkyl, hydroxy(C1-C6)alkyl, hydroxy, carboxy, —C(═O)O—(C1-C6)alkyl], carboxamido, acetoxy, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino, and arylsulfonylamino;
- —((CH2)m)heteroaryl optionally substituted with one to four substituents chosen independently from (C1-C6)alkoxy, halo(C1-C6)alkoxy, methylenedioxy, ethylendioxy, (C1-C6)acyl, (C1-C6)alkoxyalkyl, hydroxy(C1-C6)alkyl, hydroxy, carboxy, —C(═O)O—(C1-C6)alkyl], carboxamido, acetoxy, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino, and arylsulfonylamino;
- R4 is chosen from —OH, —NH((CH2)m)aryl and —NH((CH2)m)heteroaryl, each said —NH((CH2)m)aryl or —NH((CH2)m)heteroaryl optionally substituted with one to three substituents chosen independently from (C1-C6)alkoxy, halo(C1-C6)alkoxy, methylenedioxy, ethylendioxy, (C1-C6)acyl, (C1-C6)alkoxyalkyl, hydroxy(C1-C6)alkyl, hydroxy, carboxy, —C(═O)O—(C1-C6)alkyl], carboxamido, acetoxy, amino, (C1-C6)alkylamino, di(C1-C6)alkylamino, (C1-C6)alkylsulfonylamino, and arylsulfonylamino;
- R5 is
- X1 is chosen from O, N, and S(═O)2;
- R1 is chosen from hydrogen, C1-C20 hydrocarbyl, C1-C20 oxaalkyl, C1-C20 thiaalkyl, C1-C20 azaalkyl, an optionally substituted benzoquinone, an optionally substituted hydrobenzoquinone, and phenyl substituted with at least one oxygenated substituent;
- R8 and R9 are chosen independently in each occurrence from H and (C1-C3)alkyl;
- m is 0 or an integer from 1 to 10;
- n is 1 or 2;
- p is an integer from 0 to 1 and q is an integer from 1 to 4, such that the sum of p and q is an integer from 1 to 4;
- and
- t is 0, 1, or 2;
- and
- b) a pharmaceutically acceptable excipient.
17 more elements
A pharmaceutical composition, comprising
- a) a compound of formula III:
- wherein:
- Y is N;
- A is a direct bond and R2 is benzyl, such that R2-A together are benzyl;
- t is 0;
- n is 1;
- and
- R3 is —CH3;
- and
- b) a pharmaceutically acceptable excipient.
7 more elements
Dependencies are inferred from the claim text.